In the protozoan parasite Leishmania, drug resistance can be a complex phenomenon. Several metabolic pathways and membrane transporters are implicated in the resistance phenotype. To monitor the expression of these genes, we generated custom DNA microarrays with PCR fragments corresponding to 44 genes involved with drug resistance.
INTRODUCTION
Leishmania is a protozoan parasite distributed worldwide for which we have limited means to control its spread. No vaccines are available and chemotherapy relies mainly on pentavalent antimony containing drugs, although in endemic regions with high antimony resistance the palliative miltefosine appears very useful (1, 2) . Unresponsiveness of parasites to antimonials is a serious health problem and resistance has now reached epidemic proportions in parts of India (3) . Numerous resistance mechanisms have been uncovered from in vitro studies that were related to either transport defect, ampli®cation of genes coding for drug targets, or altered metabolism (reviewed in 4). Antimony is given as pentavalent antimony (SbV) sugar conjugates but the metal is likely to be reduced in vivo to the trivalent form (SbIII). Therefore, a loss of this reduction activity could lead to resistance (5) . The route of entry of SbV is not known, but reduced uptake could also lead to resistance and cells selected for SbIII resistance show a reduction in the steady-state accumulation of the metal (6) . All antimonite and arsenite resistant Leishmania mutants share a metabolic signature: a signi®cant increase in the intracellular trypanothione (TSH) level (7, 8) . TSH is a glutathione± spermidine conjugate (9) , which is formed following several enzymatic steps (Fig. 1B) . Overexpression of some of the genes in this pathway can lead to an increase in the intracellular level of TSH (10, 11) . It is proposed that an Sb± TSH conjugate is formed inside the parasite cell and the complex is either extruded outside the cell by an ATPdependent ef¯ux system (Fig. 1D ) or sequestered within a vacuole by the intracellular ABC transporter PGPA (12) . Other genes not related to the metabolic pathways shown in Figure 1D can also contribute to Sb resistance (13, 14) .
Similarly, resistance to the model antifolate drug methotrexate (MTX) in Leishmania can be explained by several mechanisms (Fig. 1A ) including reduced uptake mediated by the modulation of the expression of a series of folate transporters (FT) (15, 16) . This is often compensated for by an overexpression of the biopterin transporter BT1 (17, 18) . Ampli®cation of the target gene dihydrofolate-reductasethymidylate synthase DHFR-TS (19) or of the pterin reductase PTR1 that has folate reductase activity (20, 21) are two other frequent MTX resistance mechanisms. Modulation in the level of polyglutamylation of folates and MTX was also shown to contribute to MTX resistance in this parasite (22) .
Several different mechanisms are responsible for resistance to a drug and multiple resistance mechanisms may co-exist in the same cell and act either additively or synergistically. The multiplicity of resistance mechanisms to a certain class of drug justi®es an approach allowing the simultaneous analysis of the expression of several genes. DNA microarrays are well suited for that purpose. The utility of this technology has been demonstrated for drug responses and resistance mechanisms in microorganisms and cancer cells (23±29), and could allow the identi®cation of novel pathways potentially involved in resistance. DNA microarrays have recently been used to investigate stage-speci®c gene expression in Leishmania (30± 32). Since drug resistance in this parasite is often linked to alterations in gene expression due to either gene ampli®cation Table 1 (15) or other mechanisms (11), we chose DNA microarrays since it is well suited for analysing drug resistant mutants. The Leishmania genome-sequencing project is near completion (www.genedb.org) and most of the genes involved in the TSH biosynthetic pathway or in the folate metabolism pathway shown in Figure 1 , are now part of the public domain. We have generated custom microarrays with DNA fragments corresponding to genes related to these two metabolic pathways as well as the linked pathways of cysteine and methionine metabolism (Fig. 1 ). We present a study of the expression of these genes in Leishmania mutants selected for metal or MTX resistance.
MATERIALS AND METHODS

Cell lines and cultures
The Leishmania tarentolae wild-type cell line TarIIWT, the arsenite resistant mutant TarIIAs50.1 and the antimonite resistant mutant TarIISbIII400.1 have been described previously (8, 35) . The Leishmania major LV39 strain was selected step by step for MTX resistance in M199 medium. This process generated two independent clones named MTX60.2 and MTX60.4, both resistant to 60 mM of MTX (EC 50 of wild-type cell is 100 nM) (36) . The growth properties of the different wild-type species as well as of the drug resistant mutants were carefully monitored to ensure that cells were collected in the same growth phase.
Total RNA preparation and labelling RNA was isolated from 10 8 Leishmania cells during the mid-log growth phase using Trizol reagent (Invitrogen) as described by the manufacturer. The RNA preparation was treated with DNase I (Ambion) to avoid any genomic contamination and puri®ed further using the RNeasy kit (Qiagen). Puri®ed total RNA was quanti®ed spectrophotometrically at 260 and 280 nm, and ratios A260 nm/A280 nm between 1.9 and 2.1 were considered acceptable. RNA integrity was assessed by visualising the ribosomal bands on a 1% TAE agarose gel. RNA was converted to¯uorescent cDNA probes by direct incorporation of Cy3/Cy5-linked dUTP (Amersham Pharmacia) mediated by the Superscript II reverse transcriptase (RT) (Invitrogen) according to the supplier recommendations. For each labelling reaction, 15 mg of puri®ed RNA were spiked with two exogenous RNAs (CAB1 at 2 pg/ml and NAC1 at 5 pg/ml from Arabidopsis thaliana; Stratagene) added as references to adjust for variations in the incorporation ef®ciency of the two dyes and for differences in ®rst strand cDNA synthesis reactions. Brie¯y, total RNA was ®rst denatured by heating at 95°C for 5 min and the reverse transcription was performed at 42°C for 3 h with the RT enzyme, random nonamers and anchored oligo(dT) 25 . The RNA was then degraded by an RNase treatment and the cDNA was puri®ed using the Qiaquick PCR puri®cation kit (Qiagen). The synthesised cDNA was quanti®ed at 260 nm while the Cy3 and Cy5¯uorophor incorporations were monitored at 550 and 650 nm, respectively. Aliquots of cDNA containing 20 pmol of incorporated dye were lyophylised and stored at ±80°C until use.
DNA labelling
Total DNA was isolated using the DNAzol technique (Invitrogen). Thirty micrograms were digested with Sau3AI, puri®ed using Microcon 30 ®lter columns (Millipore) then quanti®ed at 260 nm. Two micrograms of digested DNA were labelled by direct incorporation of Cy3/Cy5-linked dUTP using a random priming method with a highly concentrated Klenow enzyme (NEB). In addition to the genomic template DNA, each labelling reaction contained random hexamers, 120 mM of each of dATP, dGTP and dCTP, 60 mM dTTP, 60 mM Cy3 or Cy5-dUTP in a Tris-MgCl 2 buffer. Reactions were performed at 37°C for 2 h. The DNA preparation was then puri®ed with Microcon 30 ®lter columns and quanti®ed using procedures similar than those described above for labelled cDNAs. Aliquots containing 20 pmol of incorporated dye were lyophylised and stored at ±80°C until use. Hybridisations were performed with the same protocol used for labelled cDNA.
Generation of customised DNA microarrays
When this work was initiated, not all genes found in Table 1 were known and some were obtained by PCR homology cloning, but with the Leishmania genome-sequencing project advancing steadily (and now almost completed) it has been possible to obtain most genes from in silico screening. The remaining exception is the cystathionine g-synthase (Table 1) . Prior to genome data, several genes were cloned using degenerated oligonucleotides derived from the conserved sequences of aligned homologues of these proteins. For all 44 genes, depending on the size and sequence, one to three pairs of primers were synthesised and used to amplify 500 bp fragments from Leishmania genomic DNA. These PCR fragments (one to three fragments per gene, see Table 1) were cloned in the pGEMt-easy vector system (Promega), which contains the sequences necessary for ampli®cation using T7 and SP6 primers. The identity of all clones was con®rmed by sequencing. For layering on DNA arrays, each cloned fragment was ampli®ed by PCR using T7 and SP6 primers, puri®ed on a Qiaquick PCR column (Qiagen) and quanti®ed using the Picogreen reagent (Molecular Probes). Aliquots containing 2 mg of each PCR fragment were transferred to a 384 well plate, dried and subsequently resuspended in 5 ml of a 50% DMSO solution. The DNA was denatured by heating at 95°C for 15 min and printed onto CMT-GAPS II slides (Corning) using an SDDC-2 Arrayer (Virtek) in a 70% humidity constant atmosphere. Slides were UV cross-linked at 200 mJ then baked at 80°C for 2 h. Printing quality controls of each slide batch include staining with ToTo-3 iodine (Molecular Probes) and hybridisation with Cy3-labelled random oligonucleotides (Spotcheck, Genetix).
Prehybridisation/hybridisation and statistical analysis
Slides were prehybridised at 42°C for 60 min in 5Q SSC, 0.1% SDS, 1% BSA, 100 mg/ml ssDNA. For hybridisation, Cy3 and Cy5 labelled cDNAs were ®rst resuspended and mixed together in the hybridisation solution (50% formamide, 5Q SSC, 0.1% SDS, 25 mg/ml ssDNA, 460 mg/ml tRNA) preheated to 42°C. The mixture was heated at 95°C for 5 min, cooled slowly to 42°C and applied under a coverslip on the array. Hybridisation was performed at 42°C for at least 12 h under immersion (Corning chambers). Slides were ®rst washed at 55°C for 5 min in 1Q SSC, 0.03% SDS. Subsequent washes were at room temperature in 0.2Q SSC and 0.05Q SSC, each for 5 min under agitation. Slides were dipped in water and 99% ethanol then dried by centrifugation. Scanning was performed using a confocal 4000XL scanner (GSI Lumonics). Spots were manually examined and those of low intensity or presenting unusual shape were ignored. Data were analysed using QuantArray software. Four different RNA preparations of each mutant and their corresponding wild-type cell line were analysed, corresponding to two dyeswapping experiments. Data were corrected for local background, and ratios were adjusted using the two spiked RNAs as references. Statistical signi®cance was calculated by the Student's test using StatView software, and the two spiked RNAs as controls. A cut-off of two for signi®cant differences was chosen although we do agree that smaller differences may also be of interest when statistically signi®cant. Genes with consistent altered expression (at least 2-fold differences) were further studied by Southern and northern blot analysis, while following standard protocols (37) to con®rm results obtained by DNA microarrays. Blots were hybridised to the same PCR DNA fragments layered on the arrays, and the hybridisation intensity was derived by densitometry analysis using an alphaImager 2000 (Alpha Innotech) with the software Alpha Ease version 4, and also a BioImage Visage 100S and compared with the signal intensity of blots hybridised with an a-tubulin probe.
RESULTS
Generation of DNA microarrays
The strategy to generate the DNA microarrays is laid out under Materials and Methods. Our goal was to build DNA 
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Transporter, MDR copy 2, Pgp AL135898 microarrays containing most of the genes known to be implicated in antimony and MTX resistance and to complete these arrays with genes known to be involved in TSH and folate metabolic pathways including some involved in cysteine and methionine metabolic pathways ( Fig. 1 ) as well as a number of`housekeeping' genes. The 44 genes investigated, with their corresponding accession numbers, are listed in Table 1 . Each PCR fragment was spotted in triplicate on the array. Arrays were hybridised to Cy3 and Cy5 labelled cDNA from the same sample preparation and hybridisation was found to be uniform (not shown). Once the spotting, hybridisation and washing conditions were optimised, and hybridisation signals could be consistently reproduced, the arrays were used for the parallel analysis of gene expression in Leishmania drug resistant mutants.
Analysis of metal resistant mutants by DNA microarrays
Our previous work on metal resistance in Leishmania has highlighted the importance of TSH biosynthesis and the increased expression of the ABC transporter PGPA (38) . All the known genes of the TSH metabolic pathway were thus included on the array. To validate the use of our custom DNA microarrays, we ®rst studied the arsenite resistant mutant TarIIAs50.1, a mutant in which PGPA is known to be overexpressed (35) and in which the level of TSH is known to be increased (7) . Most genes were equally expressed between wild-type and TarIIAs50.1, except for g-glutamylcysteine synthetase (GSH1) (P < 0.0001), the gene product of which catalyses the rate limiting step of glutathione biosynthesis, and PGPA (P < 0.0177), which according to this (Fig. 2) and other experiments were found to be overexpressed in the mutant. The same hybridisation pro®le was obtained whether the mutants were grown in the presence of drugs or in the absence of drugs for one passage (result not shown). It is also worth noting that arrays containing mostly genes derived from L.major (Table 1) are suitable for analysing the expression of genes of L.tarentolae. DNA microarray expression results were con®rmed by northern blot analysis (Fig. 2B) . While microarrays suggested a 2±3-fold overexpression, quanti®cation of northern blots indicated that GSH1 was overexpressed by 11-fold and PGPA by 15-fold (Table 2) . However, when the microarrays were scanned with a lower laser power, the fold difference values were higher and closer to northern blot values but weaker signals were lost. Thus, in some experiments, our custom microarrays became rapidly saturated for genes highly overexpressed. The antimonite resistant mutant L.tarentolae TarIISbIII400.1 has been described previously. It is already known that GSH1 and PGPA are overexpressed (8) in this strain, but revertants of these cells having lost the GSH1 containing amplicon nonetheless had higher TSH levels than wild-type cells (8) , suggesting that another gene of the TSH biosynthetic pathway might be increased. Analysis of the competitive hybridisation between labelled wild-type and TarIISbIII400.1 cDNAs on our custom DNA microarrays indeed con®rmed that PGPA and GSH1 (P < 0.0079 and P < 0.0001) were overexpressed, but we also found that the glutathione synthase (GSH2) gene, the second step in glutathione biosynthesis (Fig. 1) , was also overexpressed (P < 0.0001) (Fig. 3) . The Leishmania GSH2 gene has not yet been described but was revealed by the ongoing Leishmania genome project (accession number AL356246). The gene product shows 35 and 38% identity with the GSH synthase proteins of yeast and human (accession numbers Y138804 and BC007927), respectively. These array results were con®rmed by northern blot analysis (Fig. 3B) . In this mutant a better correlation was observed between microarrays and northern blots to estimate the fold increase in gene expression, although saturation was evident for the highly overexpressed genes ( Table 2 ). Table 2 . (C) Southern blot analysis to test whether increased RNA expression is mediated, at least in part, by gene ampli®cation. The DNA of the parasites was digested with HindIII. 1, L.tarentolae wild-type cell; 2, TarII As50.1. Sizes were determined using the 1 kb Plus DNA ladder and the 0.24±9.5 kb RNA ladder from Invitrogen.
Analysis of L.major mutants selected for MTX resistance by DNA microarrays
Our success in analysing metal resistance using DNA microarrays has prompted us to investigate MTX resistant mutants of L.major that had not been systematically characterised previously. The ®rst mutant analysed was L.major MTX60.2 and DNA microarrays have revealed that PTR1 (P < 0.0001) as well as PGPA (P < 0.0001) (Fig. 4A) were overexpressed. PTR1 is a known MTX resistance gene (39, 40) and its overexpression was con®rmed by northern blots (Fig. 4B) . In addition to PTR1, the microarrays suggested that the S-adenosylmethionine synthase gene (MAT2), recently described in L.infantum (41) and involved in a critical step in methionine metabolism (Fig. 1) , was also overexpressed (P < 0.0001). This microarray result was validated by northern blot analysis (Fig. 4B) . As for mutant TarIISbIII400.1 there was a good correlation between the fold expression determined by DNA microarrays and northern blots ( Table 2 ).
The analysis of the mutant L.major MTX60.4 using DNA microarrays has revealed a different set of genes whose expression was altered compared with the L.major MTX60.2 mutant. Indeed, DHFR-TS was overexpressed (P < 0.0001) while the expression of one of the FT genes was down regulated (P < 0.0001) (Fig. 5A ). These expression results were con®rmed by northern hybridisations where DHFR-TS RNA was increased (Fig. 5B) . Several messengers hybridised Table 2 . (C) Southern blot analysis to test whether increased RNA expression is mediated by gene ampli®cation. The DNA of the parasites was digested with HindIII (blots hybridised to GSH2 and tubulin probes); EcoRI (blot hybridised to a GSH1 probe); and BamHI (blot hybridised to a PGPA probe). 1, Leishmania tarentolae wild-type cell; 2, TarIISbIII400.1. Sizes were determined using the 1 kb Plus DNA ladder and the 0.24±9.5 kb RNA ladder from Invitrogen. to an FT probe, but the expression of at least one message was signi®cantly down-regulated (Fig. 5B , marked with an asterisk). The down-regulation of FT expression is translated into a marked decrease of folate/MTX transport in mutant cells (Fig. 5D ). There was a lack of correlation in the estimation of expression levels of DHFR-TS between microarrays and northern blots ( Table 2) .
Gene overexpression is mediated by gene ampli®cation and other mechanisms
Gene overexpression in Leishmania is often due to gene ampli®cation (33, 34) . We have tested whether DNA microarrays could be useful to detect gene ampli®cation events by carrying out competitive hybridisations with digested total DNAs derived from sensitive cells and resistant mutants labelled with Cy3 and Cy5, respectively. Results are presented for the mutant TarIISbIII400.1 in which three genes, PGPA, GSH1 and GSH2 were found to be overexpressed (Fig. 3) . While PGPA was ampli®ed, and the copy number of GSH1 was also slightly increased, GSH2 was not ampli®ed (Fig. 6 ). These array results were con®rmed by Southern blot analysis (Fig. 3C ) ( Table 2 ). While GSH1 is ampli®ed, the increase in copy number is not commensurate with the increase in RNA overexpression, suggesting that another mechanism than gene ampli®cation also contributes to GSH1 overexpression. Moreover, since GSH2 is overexpressed without gene ampli®cation (Fig. 3) , we tested whether all the other genes found to be overexpressed in the other resistant mutant studied were ampli®ed or not using Southern blots. In mutant TarIIAs50.1, overexpression of both GSH1 and PGPA is correlated to ampli®cation of their respective genes (Fig. 2C ).
In the MTX resistant mutant L.major MTX60.2, the overexpression of PTR1 is due to gene ampli®cation (Fig. 4C) .
PGPA is closely linked to PTR1 on the same locus (42,43) and thus the overexpression of PGPA observed by microarray (Fig. 4) is likely due to the co-ampli®cation of its gene. In contrast to PTR1, the MAT2 gene in L.major MTX60.2 is overexpressed (Fig. 4B ) but its gene is not ampli®ed (Fig. 4C) . In mutant L.major MTX60.4, the overexpression of DHFR-TS is due to the ampli®cation of its gene (Fig. 5C ). In the same mutant, one of the FT was down-regulated. We probed the DNA with a FT probe recognising several gene members (15) and observed a deletion event in the FT locus (Fig. 5C , marked with an asterisk). In general, a higher copy number of a gene will lead to more RNA but the correlation is only qualitative ( Table 2) . Copy number and RNA expression correlated best for PTR1 in LV39MTX60.2 and for GSH1 in TarIIAs50.1 (Table 2 ). In our analysis of DNA ampli®cation events using microarrays, we found in the mutant TarIISbIII400.1 (Fig. 6A) , a new gene corresponding to S-adenosyl homocysteine hydrolase (SAHH) (Fig. 1) , a putative drug target in Leishmania (44). This array result was validated by Southern blot analysis (Fig. 6C) . This result was in contrast to the microarray results, however, which did not show that the SAHH gene was overexpressed. A northern blot using a SAHH probe revealed that in this mutant there were two RNA species, as opposed to one in the wild-type cell (Fig. 6B) . The fold increase in expression was low, however, and explains why this was missed by the microarray analysis. Further detailed analysis has con®rmed that there is no statistical difference in the expression array data for this gene between wild-type and TarIISbIII400.1 (Table 2) .
DISCUSSION
DNA microarrays are powerful tools now being employed in the ®eld of parasitology. They have already showed their Table 2 . (C) Southern blot analysis to test whether increased RNA expression is mediated by gene ampli®cation. The DNA of the parasites was digested with HindIII except for the blot hybridised to the PTR1 probe where the DNA was digested with SacI. 1, Leishmania major wild-type cell; 2, L.major LV39 MTX60.2. Sizes were determined using the 1 kb Plus DNA ladder and the 0.24±9.5 kb RNA ladder from Invitrogen. usefulness in malaria research (45±48) and also for looking at gene expression in Trypanosoma brucei (49) . Both cDNAs and random 1 kb genomic DNAs of L.major spotted on microarrays appear to have provided useful results to study differential gene expression between L.major promastigotes and metacyclics (30±32). We took advantage of the ongoing Leishmania genome-sequencing project and analysed four diverse resistant mutants. These studies have validated the use of microarrays in studying drug resistance in Leishmania and have pinpointed new genes overexpressed either by gene ampli®cation or by other mechanisms.
A number of studies in bacterial or mammalian cells have dealt with changes of expression in the presence of drugs (24± 28) but few have dealt with the analysis of resistance per se. One example is the use of microarrays for studying the genesis of resistance to¯uconazole in Candida albicans (29) . While it was known that TSH levels were increased in TarIIAs50.1 (7), the molecular mutation responsible for this increase was unknown. In other mutants, we have shown that overexpression of GSH1 and/or of the ornithine decarboxylase gene ODC were associated with increased TSH biosynthesis (11) . This is due to GSH1 ampli®cation in TarIIAs50.1. The work presented here has also pinpointed a novel gene corresponding to GSH2, whose overexpression is possibly linked to increased TSH in metal resistant mutants. Although GSH1 has been shown to be overexpressed in a number of circumstances in several organisms including Leishmania (10), this appears to be the ®rst report of GSH2 overexpression in any drug resistant cells. While GS is not rate limiting under standard conditions, this situation could change following the ampli®cation of GSH1 in Leishmania, as observed in TarIISbIII400.1. In rats, treatment known to increase the expression of GSH1 also increase the expression of GSH2 (50). While overexpression of GSH2 in yeast does not appear to increase GSH levels (51), induction of GS increased glutathione levels in a human liver cell line (50) .
The custom DNA microarrays have also been used for the analysis of MTX resistant mutants where several genes known to be implicated in resistance, such as PTR1, DHFR-TS and FT were pinpointed. The analysis of LV39 MTX60.2 has highlighted the overexpression of MAT2. Overexpression of this gene is novel and has not been described in any other drug resistant organism. Ongoing proteomic studies have shown that overexpression of the MAT2 protein is a frequent event in MTX resistant mutants or in cells put in contact with MTX, but transfection of MAT2 alone does not seem to directly confer MTX resistance (J.Drummelsmith and M. Ouellette, unpublished) . Since the MAT2 gene is not ampli®ed, its overexpression cannot be explained by co-ampli®cation of another nearby resistance gene. Genes in Leishmania are transcribed as large polycistronic RNAs and only one region on the entire chromosome 1 appears to correspond to a pol IIlike promoter (52) . Thus, we think it is unlikely that the overexpression of MAT2 is due to a mutation in a promoterlike element of an upstream gene. Mutations in either the 5¢ or 3¢ untranslated regions of MAT2 or mutations in a trans acting factor may explain the increase in RNA level of this gene or of the other genes revealed here that are overexpressed without an increase in copy number. Because MAT2 is often overexpressed following MTX selection, we believe that it is linked to MTX selection. Since transfection excludes a direct role (unpublished observation), we must assume a more indirect one. AdoMet is not only an intermediate metabolite in methionine catabolism but also a key intracellular molecule involved in several processes (53) . One of these may be perturbed upon alteration of folate metabolism. Since folate and methionine pathways are linked (Fig. 1) , a modulation in folate metabolism may indeed have consequences on the expression of genes involved in downstream pathways.
Upon drug selection, Leishmania often uses DNA ampli®cation to overexpress its genes (33, 34) . In the mutants studied, we found that the GSH1, PGPA, PTR1 and DHFR-TS genes were ampli®ed (Figs 2±5) and that some members of the FT family were deleted. The ability of DNA microarrays to detect gene ampli®cation events is less exploited than for expression pro®ling, but it was used, for example, in the study of human breast tumours (54) . We have demonstrated the suitability of DNA microarrays to detect gene ampli®cation events in Leishmania (Fig. 6 and results not shown). While simple techniques such as comparison of digested DNA on ethidium bromide stained gels can lead to the detection of gene ampli®cation events (19, 55) , this does not identify the number of unique amplicons nor their identity. These arrays have allowed the detection of the ampli®cation of the SAHH gene in a SbIII resistant mutant (Fig. 6) . The ampli®cation of this gene does not seem to lead to an increase in RNA levels, as this was not detected using microarray. Northern blot analysis (Fig. 6) indicated that while the main message was at an estimated size of 3.5 kb, another band at 3.8 kb seems to be unique to the mutant. It is possible that this second SAHH RNA species is more easily transported or translated and thus could lead to increase gene product expression. It is intriguing that the expression of another gene of the methionine pathway is changed in drug resistant mutants, although in this case a more simple explanation can be put forward. An increase in SAHH will lead to increase homocysteine, the precursor of de novo cysteine biosynthesis, and cysteine is the main building block of TSH which is increased in mutants.
The overexpression of most genes detected in our custom arrays were linked to gene ampli®cation events. Nonetheless, two genes GSH2 and MAT2 were overexpressed without gene ampli®cation (Figs 3 and 4) and often, for other genes, the fold increase in expression is not commensurate with the level of gene ampli®cation (Table 2 ). Increased expression without ampli®cation was found previously for ODC overexpression in arsenite resistant mutants (11) and for overexpression of BT1 or PTR1 in cells grown in biopterin poor medium for prolonged periods (56) . As there seems to be no control at the level of transcription initiation in Leishmania, it is possible that an increased in RNA stability is the reason for the augmented levels of RNA, as uncovered using microarrays and con®rmed by northern blot analysis. This could either be due to changes in untranslated regions or to mutations in trans acting factors.
Overall, we have shown the utility of DNA microarrays to study drug resistance in Leishmania. Indeed, we could ®nd several genes in the various mutants that were overexpressed that correspond to known resistance gene, hence validating the technique. Our small targeted arrays have not only allowed the ef®cient analysis of several resistant mutants but have also permitted the discovery of three new genes GSH2, SAHH and MAT2, whose expression was modulated in drug resistant mutants. Once the whole genome of Leishmania become available and is put on arrays, many more genes could be found overexpressed (or repressed) and/or ampli®ed (or deleted) in the same mutants. These arrays will be a valuable tool to study the mechanisms of resistance in ®eld isolates.
